الفهرس 
Anatomy of the liverOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
Hepatocellular carcinoma is the most frequent primary tumor of the liver, the incidence of which is increasing worldwide. Cirrhosis of the liver, regardless of etiology, is considered to be the main risk factor for the onset of HCC. Hepatitis C and B virus are the main factor related to the presence of cirrhosis of the liver in patients with hepatocellular carcinoma. Transarterial chemoembolisation (TACE) is the most widely used treatment for hepatocellular carcinoma in non surgical patients not suitable for radiofrequency ablation .
To best assess the prognosis of hepatocellular carcinoma patients it is recommended that the staging system takes into account tumor stage, liver function and physical status. Currently, the BCLC system is the only staging system that accomplishes this aim. Patients who have intermediate-stage hepatocellular carcinoma according to the BCLC staging system are the optimal candidates for transcatheter arterial chemoembolization as a palliative treatment. Palliative options should aim to improve survival without greatly impairing the quality of life.
In conventional TACE therapy , tumor selectivity is achieved when chemotherapeutic agents are mixed with lipidol , to induce ischemia in tumors. In addition, there are side effects of Lipidol as it penetrates the portal venules and hepatic sinusoids and affects the hepatic microcirculation , also doxorubicin is lost from lipidol in a very short period of time .
DC Bead microspheres are a new embolic material for TACE ,in which the embolization particles are made from a unique drug –eluting bead (DEB) technology based on polyvinyl alcohol (PVA) hydrogel that has been modified with sulphonate groups. They can be loaded with a chemotherapeutic agent widely accepted for treatment of HCC.
The advantage of using it is sustained release of chemotherapeutic agent over a long period of time ,which contrasts with the more rapid release of the agents from the lipidol solution in standard TACE therapy. With a controlled gradual and local release, contact time of the drugs with the tumor is greater and plasma levels of the drugs are lower than those with standard TACE therapy, also less side effects and doubling the dose using 150 mg instead of 70 -100 mg using lipidol.
TACE DC Bead efficiency is measured by tumor response, necrosis statistically significant decrease in tumor size, percentage necrosis, and AFP levels following successive embolization .
In the end this proves better results and response of using drug eluting bead